Founded by Stanford physicians and scientists, Mobility is advancing novel medicines to treat serious diseases mediated by inflammatory processes.  These processes contribute to a range of diseases with major unmet medical needs.

The Mobility team brings deep expertise in both the underlying biology and clinical care of inflammatory diseases, positioning the company to identify and advance potential new treatments.

One of the diseases Mobility is focused on is osteoarthritis, which affects over 50 million people in the United States alone, and which lacks effective treatment options to manage symptoms and slow disease progression.  Mobility's new OA medicines are designed to reduce inflammation-associated pain and discomfort, alleviate the underlying processes that lead to joint damage, and improve patients' quality of life.

info@mobilitybio.com